Answers are grounded in this paper and cite their sources.
Aim: Liver biopsy is considered the gold standard for the diagnosis and staging of hepatic fibrosis in patients with chronic hepatitis C and is now progressively replaced by noninvasive procedures. We aimed at improving α-2-macroglobulin diagnostic value for liver fibrosis by identifying new isoforms that may be specifically related to early stages of the pathology. Materials & methods: α-2-Macroglobulin isoforms were characterized in serum samples from patients with chronic hepatitis C and mild (F1) to moderate (F2) fibrosis by proteomic methods. Results: New biological 40 kDa C-terminal α-2-macroglobulin fragments were identified as potential biomarkers of early fibrosis (fold change = 1.55; p < 0.01). Conclusion: The serum concentration of α-2-macroglobulin fragments allows a better differentiation of F1 and F2 fibrosis stages than total α-2-macroglobulin isoforms.
No takes yet. Share an insight, caveat, or question.
Batxelli-Molina et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: